Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CaridianBCT, a provider of pathogen reduction technologies, has received CE Mark approval for expanding the product treatment range of the Mirasol pathogen reduction technology system for platelets and adding the capability of storing treated apheresis-collected platelets in platelet additive solution.
Subscribe to our email newsletter
The Mirasol pathogen reduction technology system (PRT) system is a proprietary technology that uses riboflavin and UV light to reduce the levels of infectious pathogens and inactivate white cells from collected blood, improving the safety of transfused blood products.
The Mirasol system now allows the treatment of the broadest range of platelet product volumes and concentrations in the market today and provides the flexibility to store platelets in 100% plasma or an approved platelet additive solution. This enhancement incorporates and expands on all of the existing capabilities of the Mirasol PRT system for platelets treated and stored in plasma.
This approval allows CaridianBCT to offer a product that is compatible with the use of platelet additive solution, which has become an increasingly widespread practice in Western Europe. According to the company, benefits of this approach include: reduced adverse events in platelet recipients, increased plasma yield, and the associated economic benefits from selling the salvaged plasma to fractionators.
David Perez, president and CEO of CaridianBCT, said: “This CE Mark expansion allows for broader use of the Mirasol PRT system, thus helping blood establishments to further improve the safety of the blood supply against known and emerging pathogens.”